Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Interest Expenses (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Interest Expenses for 13 consecutive years, with $560000.0 as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 48.1% to $560000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, down 40.96% year-over-year, with the annual reading at $3.7 million for FY2025, 26.8% down from the prior year.
  • Interest Expenses for Q4 2025 was $560000.0 at Aytu Biopharma, up from $516000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $1.3 million in Q3 2023, with the low at $516000.0 in Q3 2025.
  • Average Interest Expenses over 3 years is $983800.0, with a median of $1.0 million recorded in 2024.
  • The sharpest move saw Interest Expenses dropped 14.77% in 2024, then crashed 48.1% in 2025.
  • Over 3 years, Interest Expenses stood at $1.3 million in 2023, then decreased by 14.77% to $1.1 million in 2024, then crashed by 48.1% to $560000.0 in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $560000.0, $516000.0, and $730000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.